Voclosporin · Lupkynis

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Lupus Nephritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Systemic Lupus Erythematosus · Phase 3 · investigational in the US

Also approved (2)
JP
  • Lupus nephritis, in combination with mycophenolate mofetil
Product first approved 2024lifesciencesbc.ca
EU
  • Active lupus nephritis in adults (with mycophenolate mofetil)
Product first approved 2022pharmaphorum.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (10)
Systemic Lupus Erythematosus
NCT06406205 · Qilu Pharmaceutical Co., Ltd.
2023-12-25 – 2028-06 · Lupus Nephritis
What this study did
Other / comorbidity
NCT01586845 · Aurinia Pharmaceuticals Inc.
2013-03 – 2015-12 · Renal Transplantation
What this study did
NCT01243983 · Lux Biosciences, Inc.
2011-02 – 2012-12 · Noninfectious Uveitis
What this study did
NCT00258713 · Aurinia Pharmaceuticals Inc.
2005-09 – 2006-07 · Psoriasis
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT04147650 · Aurinia Pharmaceuticals Inc.
2019-10-14 – 2020-10-08 · Dry Eye Syndrome, Keratoconjunctivitis Sicca
What this study did
Phase 2 (7)
Systemic Lupus Erythematosus
NCT05306873 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-11-30 – 2024-07-11 · Systemic Lupus Erythematosus
What this study did
NCT02949973 · Aurinia Pharmaceuticals Inc.
2015-06 – 2017-02-17 · Lupus Nephritis
What this study did
NCT02141672 · Aurinia Pharmaceuticals Inc.
2014-06 – 2017-01 · Lupus Nephritis
What this study did
Other / comorbidity
NCT04701528 · Leiden University Medical Center
2020-11-15 – 2022-10-25 · Covid19, Kidney Transplant Infection
What this study did
NCT03598036 · Aurinia Pharmaceuticals Inc.
2018-06-21 – 2020-05-19 · Focal Segmental Glomerulosclerosis
What this study did
NCT03597139 · Aurinia Pharmaceuticals Inc.
2018-08-13 – 2018-12-13 · Dry Eye
What this study did
NCT00270634 · Aurinia Pharmaceuticals Inc.
2006-01 – 2009-07 · Kidney Diseases
What this study did
Phase 1 (3)
Other / comorbidity
NCT05306379 · Aurinia Pharmaceuticals Inc.
2022-01-24 – 2022-04-05 · Drug-drug Interaction
What this study did
NCT02949999 · Aurinia Pharmaceuticals Inc.
2016-10 – 2016-12 · Volunteers
What this study did
Phase 4 (3)
Systemic Lupus Erythematosus
NCT07760480 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2026-04-23 – 2030-04 · Lupus Nephritis, Systemic Lupus Erythematosus (SLE)
What this study did
NCT07611214 · Aurinia Pharmaceuticals Inc.
2026-04-22 – 2029-03-02 · Lupus Nephritis
What this study did
NCT07225387 · NephroNet, Inc.
2024-10-01 – 2027-01 · Lupus Nephritis
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Lupus Nephritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Voclosporin (Lupkynis): this drugApprovedSmall moleculeCalcineurin, Cyclophilin A (leading to calcineurin inhibition)Reliable signal
NCT03021499: Number of Participants With Adjudicated Renal Response at Week 52 (52 Weeks): Voclosporin — Number of renal responders: 73/179 (40.8%); Number of renal non-responders: 106/179 (59.2%) vs Placebo Oral Capsule — Number of renal responders: 40/178 (22.5%); Number of renal non-responders: 138/178 (77.5%)
Belimumab (GSK1550188) (Benlysta)ApprovedMonoclonal antibodyBAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS)Reliable signalNo reviewed efficacy summary in this indication
Cyclosporine (Vevye)
Approved(overall)
Small moleculeCalcineurin
Partial signal(overall)
No reviewed efficacy summary in this indication
ObinutuzumabApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Extended-Release Tacrolimus (VI-0106)
Phase 3(overall)
Small moleculeCalcineurin
not yet graded(overall)
No reviewed efficacy summary in this indication
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
Nanosomal Tacrolimus
Phase 2(overall)
Small moleculeCalcineurin
not yet graded(overall)
No reviewed efficacy summary in this indication
Rapcabtagene AutoleucelPhase 2UndisclosedCD19not yet gradedNo reviewed efficacy summary in this indication
SHR-2173Phase 2UndisclosedIFNAR1 / TACInot yet gradedNo reviewed efficacy summary in this indication
VonsetamigPhase 1—BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lupkynis (Voclosporin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (1)
Phase 4Systemic Lupus ErythematosusRecruiting
Est. primary completion 2027-01 · NCT07225387 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Systemic Lupus ErythematosusRecruiting
Est. primary completion 2027-06 · NCT06406205 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
Phase 4Systemic Lupus ErythematosusRecruiting
Est. primary completion 2028-04 · NCT07760480 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 4Systemic Lupus ErythematosusRecruiting
Est. primary completion 2029-03-02 · NCT07611214 · CT.gov ↗
What to watch

See the full readout calendar ↗